Products Categories
  • Mr.Alex Yao
    总经理
    Tel: +86-0556-5209906

  • Mobile:15391842992
  • Tel:+86-0556-5209906
  • Fax:
  • URL:http://www.benropharm.cn
  • Province/state:anhui
  • City:anqing
  • Street:Lifescience zone,8#huangguan road,Daguan District,Anqing city,Anhui province ,China
  • MaxCard:
Home > Products >  Niraparib

Niraparib CAS NO.1038915-60-4

  • Min.Order: 100 Gram
  • Payment Terms: L/C,T/T
  • Available Specifications:

  • Product Details

Keywords

  • (S)-2-(4-(Piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide
  • MK-4827
  • Niraparib base

Quick Details

  • ProName: Niraparib
  • CasNo: 1038915-60-4
  • Molecular Formula: C19H20N4O
  • Appearance: white powder
  • DeliveryTime: 2 months
  • PackAge: fiber can
  • Port: shanghai port
  • ProductionCapacity: 100 Kilogram/Year
  • Purity: 99%
  • Storage: store at 2-8 ℃
  • Transportation: air transport
  • LimitNum: 100 Gram
  • Moisture Content: ≤0.5%
  • Impurity: ≤0.1%

Superiority

The quality of our products is guaranteed and the price is low!

Details

CAS number :1038915-60-4
English name :Niraparib
English alias :(S)-2-(4-(piperidin-3-yl)phenyl) -2h-indazole-7-carboxamide; MK - 482798.00%; Niraparib(MK-4827); CS-2299; iraparib; Niraparib; EOS-60867; NiChemicalbookraparibbase; MK4827(Niraparib); NiraparibUSP/EP/BP
CBNumber:CB82514860
Molecular formula :C19H20N4O
Molecular weight :320.39

Melting point :187-189°C Boiling point :463.6±45.0°C(Predicted)
Density :1.34 Storage conditions :2-8°C(protectfromlight)
Solubility :DMSO(SChemicalbooklightly),Methanol(Slightly)
Acidity coefficient (pKa):15.36±0.30(Predicted)
Form :Solid
Color :PaleYellowtoLightYellow

Nirah panitan (niraparib, commodity name Zejula) is developed by Tesaro company poly adenosine diphosphate ribose polymerase (PARP) polybosphateadenosineribosepolymerase, inhibitor, can inhibit DNA repair. Its active component is free alkali, stable composition is a molecule containing water of crystallization of p-toluene sulfonate (niraparibtosylaChemicalbooktemonohydrate) or hydrochloride (niraparibhydrochloride, The effective components in niraparibtosylatemonohydrate. And on March 27, 2017, the FDA approved the market, mainly for the treatment of recurrent epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and maintenance therapy in adult patients who have fully or partially responded to platinum-based chemotherapy drugs.

 

Other products of this supplier

lookchemhot product CAS New CAS Cas Database Article Data Chemical Catalog